[Systemic therapy for head and neck cancer-highlights of the 2024 ASCO Annual Meeting].

IF 0.8 4区医学 Q4 OTORHINOLARYNGOLOGY Hno Pub Date : 2024-11-05 DOI:10.1007/s00106-024-01523-x

Markus Blaurock, Cornelia Brunner, Chia-Jung Busch

{"title":"[Systemic therapy for head and neck cancer-highlights of the 2024 ASCO Annual Meeting].","authors":"Markus Blaurock, Cornelia Brunner, Chia-Jung Busch","doi":"10.1007/s00106-024-01523-x","DOIUrl":null,"url":null,"abstract":"Background: Systemic therapy of head and neck squamous cell carcinoma (HNSCC), in contrast to local therapy, is a very general term for the use of drugs that affect the entire organism. Immunotherapy is a subtype of systemic therapy, although the boundaries are hard to define, since the immune system is likely to play an essential role in all treatments. This article focuses on systemic therapy.Materials and methods: All abstracts and presentations on systemic therapy of HNSCC from the American Society of Clinical Oncology (ASCO) 2024 annual congress were assessed for relevance. The main contributions were reviewed and summarized.Results: For the first time, a randomized trial demonstrated a survival advantage for systemic therapy in patients with a poor performance status over best supportive care (BSC). Clinical studies using antibody-drug conjugates (ADCs) show a promising response. In addition, the neoadjuvant approach was resumed through various study approaches.Conclusion: Even in patients with a reduced general condition, systemic therapy can lead to a substantial improvement in overall survival. The systemic therapy approach remains exciting for HNSCC, with new substances and areas of application not only in the palliative situation.","PeriodicalId":55052,"journal":{"name":"Hno","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hno","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00106-024-01523-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Systemic therapy of head and neck squamous cell carcinoma (HNSCC), in contrast to local therapy, is a very general term for the use of drugs that affect the entire organism. Immunotherapy is a subtype of systemic therapy, although the boundaries are hard to define, since the immune system is likely to play an essential role in all treatments. This article focuses on systemic therapy.

Materials and methods: All abstracts and presentations on systemic therapy of HNSCC from the American Society of Clinical Oncology (ASCO) 2024 annual congress were assessed for relevance. The main contributions were reviewed and summarized.

Results: For the first time, a randomized trial demonstrated a survival advantage for systemic therapy in patients with a poor performance status over best supportive care (BSC). Clinical studies using antibody-drug conjugates (ADCs) show a promising response. In addition, the neoadjuvant approach was resumed through various study approaches.

Conclusion: Even in patients with a reduced general condition, systemic therapy can lead to a substantial improvement in overall survival. The systemic therapy approach remains exciting for HNSCC, with new substances and areas of application not only in the palliative situation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[头颈癌的系统治疗--2024 年 ASCO 年会亮点]。

背景：与局部治疗相比，头颈部鳞状细胞癌（HNSCC）的全身治疗是使用影响整个机体的药物的总称。免疫疗法是全身疗法的一种亚型，但其界限很难界定，因为免疫系统在所有疗法中都可能发挥重要作用。本文重点介绍全身疗法：对美国临床肿瘤学会（ASCO）2024 年度大会上所有关于 HNSCC 系统疗法的摘要和演讲进行了相关性评估。对主要贡献进行了回顾和总结：结果：一项随机试验首次证明，与最佳支持治疗（BSC）相比，治疗效果不佳的患者接受全身治疗具有生存优势。使用抗体药物共轭物（ADCs）的临床研究显示了良好的反应。此外，还通过各种研究方法恢复了新辅助疗法：结论：即使是全身状况较差的患者，全身治疗也能大大提高总生存率。对于 HNSCC 来说，全身治疗方法仍然令人兴奋，它不仅在姑息治疗方面有新的物质和应用领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hno 医学-耳鼻喉科学

CiteScore

1.50

自引率

33.30%

发文量

116

审稿时长

4-8 weeks

期刊介绍： HNO is an internationally recognized journal and addresses all ENT specialists in practices and clinics dealing with all aspects of ENT medicine, e.g. prevention, diagnostic methods, complication management, modern therapy strategies and surgical procedures. Review articles provide an overview on selected topics and offer the reader a summary of current findings from all fields of ENT medicine. Freely submitted original papers allow the presentation of important clinical studies and serve the scientific exchange. Case reports feature interesting cases and aim at optimizing diagnostic and therapeutic strategies. Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice.

期刊最新文献

[Impact of the coronavirus pandemic on the diagnosis and treatment of head and neck cancer]. [Unmet medical needs in otorhinolaryngology]. [Systemic therapy for head and neck cancer-highlights of the 2024 ASCO Annual Meeting]. [Chronic crusting of the ear canal with hearing loss]. [Particulars of sinogenic orbital complications in children].